next message in archive
no next message in thread
previous message in archive
Index of Subjects
This is a multi-part message in MIME format.
------=_NextPart_000_0005_01C59180.4A3D2610
Content-Type: text/plain;
charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
.. TUESDAY JULY 26 WATCH PSIV, ST0CK IS FLYING!! UP 0.21 (87.50%) on M0NDAY
.. RADAR ALERT ....RADAR ALERT.....RADAR ALERT.....RADAR ALERT
Pacific Sunset Investments Inc.
SYMB0L: PSiV
CURRENT PRICE: .40 UP 0.21 (87.50%)
5 DAY Projection: $1.25
THIS ST0CK WAS .24 0N FRIDAY JULY 22, 2005 (See Yahoo Finance)
How many times have you heard about this????
adverse drug reactions accounted for more than 2.2 million serious cases and over 100,000 deaths,
PSIV***PSIV***PSIV***PSIV***PSIV***PSIV***PSIV***PSIV***PSIV***PSIV
A study published in the Journal of the American Medical Association reported that adverse drug reactions accounted for more than 2.2 million serious cases and over 100,000 deaths, making adverse drug reactions (ADRs) one of the leading causes of hospitalization and death in the United States.
Breaking News for Pacific Sunset Investments
Pacific Sunset Investments Completes Gen ID Acquisition
HUNTINGT0N BEACH, Calif.--(BUSINESS WIRE)--May 20, 2005--Pacific Sunset Investments, Inc. ("Pacific Sunset") (0TC:PSiV announced that it has completed its acquisition of Gen-ID Lab Services, LLC, a California limited liability corporation specializing in Single Nucleotide Polymorphism analysis data. In addition, the board of directors of Pacific Sunset has appointed Douglas Freedman to its board of directors with experience in marketing. Additionally, the company has appointed Dr. Steve N. Slilaty, Ph.D., to head an Advisory Board to assist the company with reviewing new alternatives in the "SNP" field of technology.
Gen ID will provide "SNP" (Single Nucleotide Polymorphism) analysis data. The results of SNP analysis provide physicians with a more enlightened choice of drugs and they will also be able to predict the effectiveness of the drugs for individual patients. The use of an SNP test to help treat childhood leukemia is currently being used by doctors and hospitals in the United States.
Dr. Steve Slilaty is President and Chief Scientific 0fficer of Advanomics Corporation, a leading-edge biotechnology company focusing on the identification of disease related molecular targets using advanced transriptomics technologies, which he recently developed. Dr. Slilaty also is an Adjunct Professor at the Universite du Quebec in the department of Microbiology and Biotechnology. Dr. Slilaty has founded three biotechnology companies, Advanomics Corporation, Quantum Biotechnologies Inc. (now known as Qbiogene Inc.) and Geneomics 0ne Corporation. In addition, Dr. Slilaty is one of the pioneers of Gene Therapy, having developed the first Gene Transfer system in 1983.
(This is a partial clip of the news. We suggest you go read the whole release. 0ur opinion is, this is important technology. Go to yahoo or any financial site and read the news)
C0NCLUSI0N:
adverse drug reactions accounted for more than 2.2 million serious cases and over 100,000 deaths, Doesn't this say it all?
A company to watch!
AGGRESSIVE INVEST0RS TAKE N0TE N0W!
PUT Pacific Sunset Investments Inc. PSiV
0N Y0UR RADAR SCREENS N0W,
AND WATCH THIS C0MPANY STARTING N0W
IF Y0U ARE
RECEIVING THIS EMAIL, Y0U ARE AM0NG THE FIRST PUBLIC INVEST0RS T0 KN0W AB0UT
PSiV !!!!
Disclaimer:
Information within this email contains "forwardlooking statements" within
the meaning of Section 27Aof the Securities Act of 1933 and Section 21B of
the Securities Exchange Act of 1934. Any statements that express or involve
discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, goals, assumptions or future events or
performance are not statements of historical fact and may be "forward
looking statements". "Forward looking statements" are based on
expectations, estimates and projections at the time the statements are made
that involve a number of risks and uncertainties which could cause actual
results or events to differ materially from those presently anticipated.
Forward looking statements in this action may be identified through the use
of words such as "projects", "foresee", "expects", "will", "anticipates",
"estimates", "believes", "understands" or that by statements indicating
certain actions "may", "could", or "might" occur. Risk factors include
general economic and business conditions, the ability to acquire and develop
specific projects, the ability to fund operations and changes in consumer
and business consumption habits and other factors overwhich the company has
little or no control. The publisher of this newsletter does not represent
that the information contained in this message states all material facts or
does not omit a material fact necessary to make the statements therein not
misleading. All information provided within this email pertaining to
investing, ST0CKs, securities must be understood as information provided and
not investment advice. The publisher of this newsletter advises all readers
and subscribers to seek advice from a registered professional securities
representative before deciding to trade in ST0CKs featured within this
email. None of the material within this report shall be construed as any
kind of investment advice or solicitation. Many of these companies are on
the verge of bankruptcy. You can lose all your money by investing in this
ST0CK. We urge you to read the company's SEC filings now, before you invest.
The publisher of this newsletter is not a registered invstment advisor.
Subscribers should not view information herein as legal, tax, accounting or
investment advice. In compliance with the SecuritiesAct of 1933, Section
17(b), The publisher of this newsletter is contracted to receive two hundred
thousand free trading shares from a third party, not an officer, director or
affiliate shareholder for the circulation of this report. Be aware of an
inherent conflict of interest resulting from such compensation due to the
fact that this is a paid advertisement and is not without bias. The party
that paid us has a position in the ST0CK they will sell at anytime without
notice. This could have a negative impact on the price of the ST0CK, causing
you to lose money. All factual information in this report was gathered from
public sources, including but not limited to SEC filings, Company Websites
and Company Press Releases. The publisher of this newsletter believes this
information to be reliable but can make no guarantee as to its accuracy or
completeness. Use of the material within this email constitutes your
acceptance of these terms
------=_NextPart_000_0005_01C59180.4A3D2610
Content-Type: text/html;
charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML><HEAD>
<META http-equiv=Content-Type content="text/html; charset=iso-8859-1">
<META content="MSHTML 6.00.2800.1498" name=GENERATOR>
<STYLE></STYLE>
</HEAD>
<BODY bgColor=#ffffff>
<DIV><FONT face=Arial size=2>.. TUESDAY JULY 26 WATCH PSIV, ST0CK IS
FLYING!! UP 0.21 (87.50%) on M0NDAY <BR>.. RADAR ALERT .....RADAR
ALERT.....RADAR ALERT.....RADAR ALERT<BR> </FONT></DIV>
<DIV> </DIV>
<DIV><FONT face=Arial size=2>Pacific Sunset Investments Inc.<BR>SYMB0L:
PSiV<BR>CURRENT PRICE: .40 UP 0.21 (87.50%)<BR>5
DAY Projection: $1.25<BR> <BR>THIS ST0CK WAS .24 0N FRIDAY JULY 22,
2005 (See Yahoo Finance)<BR> <BR>How many times have you heard about
this????<BR>adverse drug reactions accounted for more than 2.2 million serious
cases and over 100,000 deaths,
<BR> <BR>PSIV***PSIV***PSIV***PSIV***PSIV***PSIV***PSIV***PSIV***PSIV***PSIV<BR> <BR>A
study published in the Journal of the American Medical Association reported that
adverse drug reactions accounted for more than 2.2 million serious cases and
over 100,000 deaths, making adverse drug reactions (ADRs) one of the leading
causes of hospitalization and death in the United States. <BR> <BR>Breaking
News for Pacific Sunset Investments<BR> <BR>Pacific Sunset Investments
Completes Gen ID Acquisition<BR>HUNTINGT0N BEACH, Calif.--(BUSINESS WIRE)--May
20, 2005--Pacific Sunset Investments, Inc. ("Pacific Sunset") (0TC:PSiV
announced that it has completed its acquisition of Gen-ID Lab Services, LLC, a
California limited liability corporation specializing in Single Nucleotide
Polymorphism analysis data. In addition, the board of directors of Pacific
Sunset has appointed Douglas Freedman to its board of directors with experience
in marketing. Additionally, the company has appointed Dr. Steve N. Slilaty,
Ph.D., to head an Advisory Board to assist the company with reviewing new
alternatives in the "SNP" field of technology. <BR> <BR>Gen ID will provide
"SNP" (Single Nucleotide Polymorphism) analysis data. The results of SNP
analysis provide physicians with a more enlightened choice of drugs and they
will also be able to predict the effectiveness of the drugs for individual
patients. The use of an SNP test to help treat childhood leukemia is currently
being used by doctors and hospitals in the United States. <BR> <BR>Dr.
Steve Slilaty is President and Chief Scientific 0fficer of Advanomics
Corporation, a leading-edge biotechnology company focusing on the identification
of disease related molecular targets using advanced transriptomics technologies,
which he recently developed. Dr. Slilaty also is an Adjunct Professor at the
Universite du Quebec in the department of Microbiology and Biotechnology. Dr.
Slilaty has founded three biotechnology companies, Advanomics Corporation,
Quantum Biotechnologies Inc. (now known as Qbiogene Inc.) and Geneomics 0ne
Corporation. In addition, Dr. Slilaty is one of the pioneers of Gene Therapy,
having developed the first Gene Transfer system in 1983. <BR> <BR>(This is
a partial clip of the news. We suggest you go read the whole
release. 0ur opinion is, this is important technology. Go to yahoo
or any financial site and read the news)<BR> <BR>C0NCLUSI0N:<BR>adverse
drug reactions accounted for more than 2.2 million serious cases and over
100,000 deaths, Doesn't this say it all? <BR> <BR> A company to
watch!<BR> <BR>AGGRESSIVE INVEST0RS TAKE N0TE N0W! <BR>PUT Pacific Sunset
Investments Inc. PSiV<BR>0N Y0UR RADAR SCREENS N0W,<BR>AND WATCH THIS C0MPANY
STARTING N0W<BR> <BR>IF Y0U ARE<BR>RECEIVING THIS EMAIL, Y0U ARE AM0NG THE
FIRST PUBLIC INVEST0RS T0 KN0W AB0UT<BR>PSiV !!!!<BR> </FONT></DIV>
<DIV> </DIV>
<DIV><FONT face=Arial size=2>Disclaimer: <BR>Information within this email
contains "forwardlooking statements" within <BR>the meaning of Section 27Aof the
Securities Act of 1933 and Section 21B of <BR>the Securities Exchange Act of
1934. Any statements that express or involve <BR>discussions with respect to
predictions, expectations, beliefs, <BR>plans, projections, objectives, goals,
assumptions or future events or <BR>performance are not statements of historical
fact and may be "forward <BR>looking statements". "Forward looking statements"
are based on <BR>expectations, estimates and projections at the time the
statements are made <BR>that involve a number of risks and uncertainties which
could cause actual <BR>results or events to differ materially from those
presently anticipated. <BR>Forward looking statements in this action may be
identified through the use <BR>of words such as "projects", "foresee",
"expects", "will", "anticipates", <BR>"estimates", "believes", "understands" or
that by statements indicating <BR>certain actions "may", "could", or "might"
occur. Risk factors include <BR>general economic and business conditions, the
ability to acquire and develop <BR>specific projects, the ability to fund
operations and changes in consumer <BR>and business consumption habits and other
factors overwhich the company has <BR>little or no control. The publisher of
this newsletter does not represent <BR>that the information contained in this
message states all material facts or <BR>does not omit a material fact necessary
to make the statements therein not <BR>misleading. All information provided
within this email pertaining to <BR>investing, ST0CKs, securities must be
understood as information provided and <BR>not investment advice. The publisher
of this newsletter advises all readers <BR>and subscribers to seek advice from a
registered professional securities <BR>representative before deciding to trade
in ST0CKs featured within this <BR>email. None of the material within this
report shall be construed as any <BR>kind of investment advice or solicitation.
Many of these companies are on <BR>the verge of bankruptcy. You can lose all
your money by investing in this <BR>ST0CK. We urge you to read the company's SEC
filings now, before you invest. <BR>The publisher of this newsletter is not a
registered invstment advisor. <BR>Subscribers should not view information herein
as legal, tax, accounting or <BR>investment advice. In compliance with the
SecuritiesAct of 1933, Section <BR>17(b), The publisher of this newsletter is
contracted to receive two hundred <BR>thousand free trading shares from a
third party, not an officer, director or <BR>affiliate shareholder for the
circulation of this report. Be aware of an <BR>inherent conflict of interest
resulting from such compensation due to the <BR>fact that this is a paid
advertisement and is not without bias. The party <BR>that paid us has a position
in the ST0CK they will sell at anytime without <BR>notice. This could have a
negative impact on the price of the ST0CK, causing <BR>you to lose money. All
factual information in this report was gathered from <BR>public sources,
including but not limited to SEC filings, Company Websites <BR>and Company Press
Releases. The publisher of this newsletter believes this <BR>information to be
reliable but can make no guarantee as to its accuracy or <BR>completeness. Use
of the material within this email constitutes your <BR>acceptance of these
terms</FONT></DIV></BODY></HTML>
------=_NextPart_000_0005_01C59180.4A3D2610--
next message in archive
no next message in thread
previous message in archive
Index of Subjects